Do analysts recommend CCM or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CCM or MGRX?

Concord Medical Services has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Concord Medical Services $65.85M 0.30 -$13.27M N/A N/A Mangoceuticals $460K 13.81 -$20.64M -$1.49 N/A

Does the media favor CCM or MGRX?

In the previous week, Mangoceuticals had 1 more articles in the media than Concord Medical Services. MarketBeat recorded 2 mentions for Mangoceuticals and 1 mentions for Concord Medical Services. Mangoceuticals' average media sentiment score of 1.23 beat Concord Medical Services' score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Concord Medical Services 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mangoceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MRAI or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MRAI or MGRX more profitable?

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -4,639.13%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Mangoceuticals -4,639.13% -112.00% -104.96%

Does the media prefer MRAI or MGRX?

In the previous week, Mangoceuticals had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Mangoceuticals and 1 mentions for Marpai. Mangoceuticals' average media sentiment score of 1.23 beat Marpai's score of 0.50 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marpai 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mangoceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MGRX or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, MGRX or BMGL?

Basel Medical Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mangoceuticals $460K 13.81 -$20.64M -$1.49 N/A Basel Medical Group $8.90M 1.04 -$9.50M N/A N/A

Does the media refer more to MGRX or BMGL?

In the previous week, Basel Medical Group had 5 more articles in the media than Mangoceuticals. MarketBeat recorded 7 mentions for Basel Medical Group and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.23 beat Basel Medical Group's score of 0.61 indicating that Mangoceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mangoceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Basel Medical Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BRTX or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ADVB or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Mangoceuticals (MGRX) Competitors

$0.37 +0.01 (+2.72%)

As of 10:57 AM Eastern

Compare

MGRX vs. CCM, MRAI, BMGL, BRTX, and ADVB

Should you buy Mangoceuticals stock or one of its competitors? MarketBeat compares Mangoceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mangoceuticals include Concord Medical Services (CCM), Marpai (MRAI), Basel Medical Group (BMGL), Biorestorative Therapies (BRTX), and Advanced Biomed (ADVB). These companies are all part of the "healthcare" industry.

How does Mangoceuticals compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Concord Medical Services has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,639.13%. Concord Medical Services' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Concord Medical Services has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$65.85M	0.30	-$13.27M	N/A	N/A
Mangoceuticals	$460K	13.81	-$20.64M	-$1.49	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mangoceuticals had 1 more articles in the media than Concord Medical Services. MarketBeat recorded 2 mentions for Mangoceuticals and 1 mentions for Concord Medical Services. Mangoceuticals' average media sentiment score of 1.23 beat Concord Medical Services' score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Concord Medical Services	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mangoceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Concord Medical Services has a beta of -0.97, suggesting that its stock price is 197% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market.

56.7% of Mangoceuticals shares are owned by institutional investors. 46.5% of Concord Medical Services shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Concord Medical Services beats Mangoceuticals on 6 of the 11 factors compared between the two stocks.

How does Mangoceuticals compare to Marpai?

Marpai (NASDAQ:MRAI) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -4,639.13%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

In the previous week, Mangoceuticals had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Mangoceuticals and 1 mentions for Marpai. Mangoceuticals' average media sentiment score of 1.23 beat Marpai's score of 0.50 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marpai	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mangoceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mangoceuticals has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.52	-$28.75M	-$0.87	N/A
Mangoceuticals	$460K	13.81	-$20.64M	-$1.49	N/A

Marpai has a beta of 4.92, meaning that its share price is 392% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.28, meaning that its share price is 128% more volatile than the broader market.

49.8% of Marpai shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Marpai and Mangoceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Mangoceuticals compare to Basel Medical Group?

Mangoceuticals (NASDAQ:MGRX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Basel Medical Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	13.81	-$20.64M	-$1.49	N/A
Basel Medical Group	$8.90M	1.04	-$9.50M	N/A	N/A

Mangoceuticals has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market.

Basel Medical Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,639.13%. Basel Medical Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,639.13%	-112.00%	-104.96%
Basel Medical Group	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Basel Medical Group had 5 more articles in the media than Mangoceuticals. MarketBeat recorded 7 mentions for Basel Medical Group and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.23 beat Basel Medical Group's score of 0.61 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mangoceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Basel Medical Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.7% of Mangoceuticals shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Basel Medical Group beats Mangoceuticals on 6 of the 11 factors compared between the two stocks.

How does Mangoceuticals compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biorestorative Therapies has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.28, indicating that its stock price is 128% more volatile than the broader market.

Biorestorative Therapies has a net margin of -3,088.27% compared to Mangoceuticals' net margin of -4,639.13%. Mangoceuticals' return on equity of -112.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

In the previous week, Mangoceuticals had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 2 mentions for Mangoceuticals and 1 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 1.87 beat Mangoceuticals' score of 1.23 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company	Overall Sentiment
Biorestorative Therapies	Very Positive
Mangoceuticals	Positive

Biorestorative Therapies has higher earnings, but lower revenue than Mangoceuticals. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	25.06	-$14.24M	-$1.07	N/A
Mangoceuticals	$460K	13.81	-$20.64M	-$1.49	N/A

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Comparatively, 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Mangoceuticals beats Biorestorative Therapies on 7 of the 13 factors compared between the two stocks.

How does Mangoceuticals compare to Advanced Biomed?

Advanced Biomed (NASDAQ:ADVB) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

56.7% of Mangoceuticals shares are held by institutional investors. 27.0% of Advanced Biomed shares are held by company insiders. Comparatively, 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Advanced Biomed and Advanced Biomed both had 2 articles in the media. Mangoceuticals' average media sentiment score of 1.23 beat Advanced Biomed's score of 0.45 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Advanced Biomed	Neutral
Mangoceuticals	Positive

Advanced Biomed has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,639.13%. Advanced Biomed's return on equity of 87.74% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Biomed	N/A	87.74%	64.49%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Advanced Biomed has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.28, meaning that its stock price is 128% more volatile than the broader market.

Advanced Biomed has higher earnings, but lower revenue than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	1.10
Mangoceuticals	$460K	13.81	-$20.64M	-$1.49	N/A

Summary

Advanced Biomed beats Mangoceuticals on 7 of the 11 factors compared between the two stocks.

Get Mangoceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGRX vs. The Competition

Export

Metric	Mangoceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.35M	$2.99B	$6.76B	$12.50B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-0.25	18.55	26.93	24.41
Price / Sales	13.81	817.94	586.18	117.36
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	0.40	4.21	10.94	6.33
Net Income	-$20.64M	$64.26M	$3.58B	$330.66M
7 Day Performance	-0.75%	-3.32%	-2.10%	-0.66%
1 Month Performance	3.73%	2.34%	3.21%	-0.14%
1 Year Performance	-75.66%	20.50%	26.34%	20.16%

Mangoceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGRX Mangoceuticals	0.9874 of 5 stars	$0.37 +2.7%	N/A	-76.5%	$6.35M	$460K	N/A	3	Positive News Gap Down
CCM Concord Medical Services	0.592 of 5 stars	$4.39 flat	N/A	-16.4%	$19.05M	$65.85M	N/A	970
MRAI Marpai	N/A	$0.70 -2.5%	N/A	-52.1%	$18.68M	$34.87M	N/A	150	Gap Down
BMGL Basel Medical Group	1.0535 of 5 stars	$8.35 flat	N/A	-77.3%	$13.07M	$14.55M	N/A	36	News Coverage Gap Down High Trading Volume
BRTX Biorestorative Therapies	1.1558 of 5 stars	$0.40 flat	N/A	-79.1%	$10.19M	$360K	N/A	7	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGRX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mangoceuticals (MGRX) Competitors

MGRX vs. CCM, MRAI, BMGL, BRTX, and ADVB

How does Mangoceuticals compare to Concord Medical Services?

Summary

How does Mangoceuticals compare to Marpai?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Summary

How does Mangoceuticals compare to Biorestorative Therapies?

Summary

How does Mangoceuticals compare to Advanced Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mangoceuticals (MGRX) Competitors

MGRX vs. CCM, MRAI, BMGL, BRTX, and ADVB

How does Mangoceuticals compare to Concord Medical Services?

Is CCM or MGRX more profitable?

Which has stronger earnings and valuation, CCM or MGRX?

Do analysts recommend CCM or MGRX?

Does the media favor CCM or MGRX?

Which has more volatility and risk, CCM or MGRX?

Do institutionals & insiders hold more shares of CCM or MGRX?

Summary

How does Mangoceuticals compare to Marpai?

Is MRAI or MGRX more profitable?

Does the media prefer MRAI or MGRX?

Which has better earnings and valuation, MRAI or MGRX?

Which has more volatility and risk, MRAI or MGRX?

Do institutionals & insiders believe in MRAI or MGRX?

Do analysts recommend MRAI or MGRX?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Which has better valuation and earnings, MGRX or BMGL?

Which has more risk & volatility, MGRX or BMGL?

Is MGRX or BMGL more profitable?

Do analysts recommend MGRX or BMGL?

Does the media refer more to MGRX or BMGL?

Do institutionals and insiders hold more shares of MGRX or BMGL?

Summary

How does Mangoceuticals compare to Biorestorative Therapies?

Do analysts recommend BRTX or MGRX?

Which has more risk and volatility, BRTX or MGRX?

Is BRTX or MGRX more profitable?

Does the media prefer BRTX or MGRX?

Which has higher valuation & earnings, BRTX or MGRX?

Do insiders and institutionals believe in BRTX or MGRX?

Summary

How does Mangoceuticals compare to Advanced Biomed?

Do insiders & institutionals hold more shares of ADVB or MGRX?

Do analysts prefer ADVB or MGRX?

Does the media favor ADVB or MGRX?

Is ADVB or MGRX more profitable?

Which has more risk and volatility, ADVB or MGRX?

Which has stronger valuation and earnings, ADVB or MGRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools